Common Diuretic Linked to Home Blood Pressure Lowering After Stroke
The REDUCE trial found that adding the diuretic spironolactone to standard post-stroke care significantly lowered systolic blood pressure in patients with uncontrolled hypertension. The findings suggest a new therapeutic approach to reducing the risk of recurrent strokes.
Why it matters
This medical research provides a potential new standard of care for stroke survivors, which could improve long-term health outcomes and reduce mortality.
Adding spironolactone to post-stroke care lowered home systolic blood pressure (SBP) at 3 months compared with standard care in adults with uncontrolled hypertension after ischemic stroke or intracerebral hemorrhage, according to REDUCE trial results presented as a late-breaking abstract at the American Heart Association (AHA) Scientific Sessions 2026.1
At 3 months, home SBP was 125.6 mm Hg with spironolactone and 133.3 mm Hg with standard care (mean difference, −7.7 mm Hg; 95% CI, −11.6 to −3.8; P = .0002). More participants receiving spironolactone reached a blood pressure (BP) target below 130/80 mm Hg (52% vs 30%; P = .01), and the SBP reduction persisted at 6 months.1
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in